India, Oct. 20 -- Drugmaker AbbVie Inc. (ABBV) announced Tuesday that Health Canada has approved SKYRIZI (risankizumab) to treat children with moderate to severe plaque psoriasis.
The treatment will be given for pediatric patients aged 6 to <18 years of age with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Separately, AbbVie announced a multi-year partnership with McLaren Racing to become an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team.
Regarding the Health Canada Approval, the company noted that Psoriasis is a chronic inflammatory disease that can begin during childhood or adolescence. In the patients, nearly one-third develop symptoms before age 18.
SKYRIZI is...